United TherapeuticsNASDAQ: UTHR

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The biotechnology industry is known for its potential to provide innovative medical treatments and attractive investment opportunities, but successful investing in these companies requires a thorough understanding of their product pipelines, regulatory environments, and market factors.

United Therapeutics (UTHR) has strong growth characteristics that may enable it to significantly outperform the market.

Curious about selecting powerful stocks that outperform the market for your investment portfolio? Turn to the Zacks Style Scores for guidance.

United Therapeutics (UTHR) exceeded expectations with its earnings and sales in the first quarter of 2024, driven by strong Tyvaso sales.

While the revenue and EPS figures for United Therapeutics (UTHR) provide insight into its performance in the first quarter of 2024, it may be beneficial to also assess how certain key metrics stack up against Wall Street forecasts and the figures from the same period last year.